NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP (NYSE: XIFR). Shareholders who purchased shares of XIFR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/xplr-infrastructure-lp-f-k-a-nextera-energ ...

NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Vestis Corporation (NYSE: VSTS). Shareholders who purchased shares of VSTS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/vestis-corporation-loss-submission-form/?id=157785&from=3 CLASS PERIOD: May 2, 20 ...

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Hims was engaged in the "deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk;" (2) as a result, there was a substantial risk that the Company's collaboration with Novo Nordisk would be terminated; and (3) as a result of the foregoing, defendants' positive statements about the Company's bu ...

Company Overview - Barnes & Noble Education, Inc. operates and manages campus bookstores, e-commerce sites, and digital courseware platforms for colleges, universities, and K–12 institutions across the United States [3] Allegations and Investigation - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Barnes & Noble, stemming from allegations of providing potentially misleading business information to the investing public [1] - On July 18, 2025, Barnes & Noble announced a delay in filing its annual report for the fiscal year ended May 3, 2025, due to an ongoing internal investigation into its digital sales recording methods [4] - Initial findings from the investigation suggest that Barnes & Noble may have overstated its accounts receivable by up to $23 million and expects to disclose material weaknesses in its internal controls [4] Market Reaction - Following the announcement of the investigation and the delay in filing, Barnes & Noble's stock price fell by $2.36 per share, or 21.02%, closing at $8.87 per share on July 21, 2025 [5]

Core Viewpoint - DJS Law Group is investigating GeneDx Holdings Corp. for potential violations of securities laws, focusing on allegations of fraudulent activities and misleading statements made by the company [1][2]. Group 1: Investigation Details - The investigation is centered on whether GeneDx made false or misleading statements or failed to disclose material information relevant to investors [2]. - A report by Grizzly Research claims that GeneDx's growth is largely an illusion, driven by fraudulent schemes aimed at manipulating Medicaid and Medicare programs to artificially inflate revenue [2]. - Allegations include that GeneDx inflated earnings through the unlawful practice of "code stacking," which allows billing for services that do not meet appropriate standards [2]. Group 2: Insider Trading Allegations - The report also alleges that CEO Katherine Stueland and CFO Kevin Feeley have routinely sold their shares upon vesting without participating in open market acquisitions, suggesting insider awareness of potential threats to the business [2]. Group 3: DJS Law Group's Focus - DJS Law Group aims to enhance investor returns through balanced counseling and aggressive advocacy, specializing in securities class actions and corporate governance litigation [2].

NEW YORK, July 21, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by iTeos Therapeutics, Inc. (NASDAQ: ITOS) and its board of directors concerning the proposed acquisition of the company by Concentra Biosciences, LLC. Stockholders will receive $10.047 and one contingent value right for each share of iTeos Therapeutics stock that they hold. The transaction is expected to close in the third quarter of 2025.If you are a stockholder of iTeos Therapeutics, Inc. and are ...

NEW YORK, July 21, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS).Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/hims-hers-health-inc-loss-submission-form/?id=157181&from=4CLASS PERIOD: April 29, ...

Joining me now, Texas Dynamo and Congresswoman Jasmine Crockett. She's a member of the Judiciary and Oversight and Government Reform Committees. Good to have you back on the show, Congresswoman.So, um, at Trump's direction, AG Bondi requested the release of the grand jury testimony. Why not the entire trove of Epstein documents. Because judiciary committee Democrats want a hearing with Bondie on the Epstein case.And by the way, you're a lawyer. What would you ask her. There's a lot that I would ask, Pam Bon ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Organon & Co. regarding a class action lawsuit due to alleged misleading statements and concealment of material facts related to the company's capital allocation and dividend strategy [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that Organon & Co. provided overly positive statements to investors while concealing significant adverse facts about its priorities, particularly regarding capital allocation and a debt reduction strategy following the acquisition of Dermavant [3]. - The company reportedly reduced its regular quarterly dividend by 70%, which was not disclosed to investors prior to the announcement [3]. Stock Price Impact - Following the announcement of the dividend cut, Organon's stock price fell from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [3]. Class Action Details - The class period for the lawsuit is defined as October 31, 2024, to April 30, 2025, and shareholders are encouraged to register for participation in the class action [3][4]. - The deadline for shareholders to seek lead plaintiff status is July 22, 2025, and there is no cost or obligation to participate in the case [4]. Firm's Commitment - The Gross Law Firm emphasizes its mission to protect investors' rights and ensure companies adhere to responsible business practices, seeking recovery for losses incurred due to misleading statements [5].

Those who purchasedNASDAQ: PCRX shares should contact the Shareholders Foundation, Inc. CONTACT: SAN DIEGO, July 16, 2025 /PRNewswire/ -- Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Pacira BioSciences, Inc. (NASDAQ: PCRX) shares. Investors who purchased shares of Pacira BioSciences, Inc. prior to August 2023 and continue to hold any of thoseNASDAQ: PCRX shares also have certain options and contact the Shareholders Foundation at [email protected] or call +1(858) ...